Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 11, pp. 951-963
Open Access | Times Cited: 206

Showing 1-25 of 206 citing articles:

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Karolina Drożdż, Katarzyna Nabrdalik, Weronika Hajzler, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 78
Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine
Huiling Tan, Yue Tong, Zhengfang Chen, et al.
International Journal of Biological Sciences (2022) Vol. 19, Iss. 1, pp. 66-88
Open Access | Times Cited: 50
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q. Huang, et al.
Hepatology Research (2022) Vol. 52, Iss. 6, pp. 497-507
Open Access | Times Cited: 47
Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
S Kamata, Akihiro Honda, Isao Ishii
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1264-1264
Open Access | Times Cited: 35
Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
Zeyu Wang, Du Huiqing, Ying Zhao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 27
Nutritional Support for Alcoholic Liver Disease
Tomoko Tadokoro, Asahiro Morishita, Takashi Himoto, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1360-1360
Open Access | Times Cited: 24
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study
Takao Miwa, Satoko Tajirika, Nanako Imamura, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1158-1158
Open Access | Times Cited: 13
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
Nobuharu Tamaki, Shun‐ichi Wakabayashi, Takefumi Kimura, et al.
Hepatology Research (2024) Vol. 54, Iss. 8, pp. 753-762
Closed Access | Times Cited: 13
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 13
Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease
Shun‐ichi Wakabayashi, Nobuharu Tamaki, Takefumi Kimura, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 6, pp. 494-503
Closed Access | Times Cited: 10
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 8, pp. 1033-1041
Closed Access | Times Cited: 9
Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes
Ito H, Ryota Someya, Takahiro Koyanagi, et al.
Journal of Diabetes Investigation (2025)
Open Access | Times Cited: 1
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
Wah‐Kheong Chan, Soek‐Siam Tan, Siew‐Pheng Chan, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 37, Iss. 5, pp. 795-811
Open Access | Times Cited: 35
Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups
Aya Sugiyama, Akemi Kurisu, E Bunthen, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 35
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
Masato Yoneda, Takashi Kobayashi, Yasushi Honda, et al.
Hepatology Communications (2022) Vol. 6, Iss. 9, pp. 2273-2285
Open Access | Times Cited: 30
The greater impact of PNPLA3 polymorphism on liver‐related events in Japanese non‐alcoholic fatty liver disease patients: A multicentre cohort study
Yuya Seko, Kanji Yamaguchi, Toshihide Shima, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2210-2219
Open Access | Times Cited: 22
Increased RTN3 phenocopies nonalcoholic fatty liver disease by inhibiting the AMPK–IDH2 pathway
Hao Huang, Shuai Guo, Yaqin Chen, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 17
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Robert G. Gish, Jian‐Gao Fan, Zahra Dossaji, et al.
Hepatology International (2024)
Closed Access | Times Cited: 8
Deciphering metabolic dysfunction‐associated steatotic liver disease: insights from predictive modeling and clustering analysis
Kazuma Mori, Yukinori Akiyama, Marenao Tanaka, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 7, pp. 1382-1393
Open Access | Times Cited: 7
Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease
Takanobu Iwadare, Takefumi Kimura, Taiki Okumura, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 6
Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial
Daisuke Ito, Satoshi Shimizu, Akifumi Haisa, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 9, pp. 1220-1230
Open Access | Times Cited: 6
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 836-848
Open Access | Times Cited: 6
A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
Dana Ivancovsky‐Wajcman, Christopher J. Byrne, John Dillon, et al.
Hepatology (2024)
Open Access | Times Cited: 6
Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung‐Yi Mak, Man‐Fung Yuen, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S103-S122
Open Access | Times Cited: 25
Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses
Kazuma Mori, Marenao Tanaka, Itaru Hosaka, et al.
Hypertension Research (2023) Vol. 46, Iss. 5, pp. 1110-1121
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top